www.virology-education.com
EVALUATION REPORT
17TH INTERNATIONAL WORKSHOP ON
HIVHepatitis
WASHINGTON DC, USA • 8 - 10 JUNE 2016
CLINICAL PHARMACOLOGYOF HIV & HEPATITIS THERAPY
HIVHepatitis
2EVALUATION REPORT 17th International Workshop on Clinical Pharmacology of HIV & Hepatitis Therapy 8 - 10 June 2016, Washington, DC, USA
EXECUTIVE SUMMARY
The 17TH INTERNATIONAL WORKSHOP ON CLINICAL PHARMACOLOGY OF HIV & HEPATITIS THERAPY was held on 8-10 June 2016 at the Washington Plaza Hotel and was attended by nearly 160 participants from 20 countries. The meeting gathers a steady international community of researchers and healthcare professionals.
Professional background of the participants is reflected in the below chart:
Professional Background
Pharmacologist; 43%
Pharmacist; 20%
Researcher; 19%Other; 8%
Cl inician; 6%
Student; 5%
Marketing person; 1%
IMPACT97% of the respondents indicated that the content of the workshop increased their knowledge, and 83% indicated that the workshop is beneficial for the clinical management of their patients. Furthermore, 86% of the respondents indicated that they intend to incorporate the new information into their daily practice after attending the workshop.
On average, 90% of the respondents indicated that the learning objectives were met.
PROGRAMThe program included 25 invited lectures, 15 oral abstract presentations, three poster viewing sessions, a pro-con debate and two roundtable discussions. Ample time was allocated for discussion. Just as last year, 3/4 day was dedicated to Hepatitis C resistance, by way of incorporating the 11th International Workshop on Hepatitis C: Resistance and New Compounds. The presentation of, Dr Catia Marzolini entitled “Will we see the Back of DDIs” (Back to the Future: 40 years of Clinical Pharmacology) received the highest score (an average of 4,5 (out of 5)) on all categories.
GENERAL MEETING SCORE98% of the participants rated the meeting experience as excellent/good. 96% would recommend this meeting to their peers and 89% intend to attend next year.
The Organizing Committee and the Organizing Secretariat are pleased with the evaluation results of the 17th edition of this meeting and are looking forward to an even more successful edition in 2017!
“Best meeting I go to each year”
HIVHepatitis
3EVALUATION REPORT 17th International Workshop on Clinical Pharmacology of HIV & Hepatitis Therapy 8 - 10 June 2016, Washington, DC, USA
CONTENT
Executive Summary .............................................................................. 2
Introduction ........................................................................................... 4
Meeting Partners .................................................................................. 6
Corporate Supporters ........................................................................... 7
Program Committee ............................................................................. 8
Organizing Committee .......................................................................... 9
Scientific Committee ...........................................................................10
Industry Liaison Board ........................................................................11
Participants’ Feedback ........................................................................12
Meeting Demographics ........................................................................17
Conclusion ...........................................................................................18
List of Participants ...............................................................................19
HIVHepatitis
4EVALUATION REPORT 17th International Workshop on Clinical Pharmacology of HIV & Hepatitis Therapy 8 - 10 June 2016, Washington, DC, USA
INTRODUCTION
This is the evaluation report of the 17th International Workshop on Clinical Pharmacology of HIV & Hepatitis Therapy, held on 8 - 10 June 2016 at the Washington Plaza Hotel in Washington DC, USA. The Organizing Commitee and the Organizing Secretariat highly value the opinion of the participants in order to further improve the quality of the workshop. Participants were asked to complete an evaluation form to share their opinion on several subjects.
BACKGROUNDUnderstanding the clinical pharmacology of antiretroviral therapy is pivotal to designing optimal treatment and prevention strategies for HIV & Hepatitis infection. Drug exposure is significantly influenced by drug interactions, medication taking behavior, and patients’ physiologic and genetic characteristics. These factors are central to determining therapeutic efficacy, failure or toxicity. Despite great progress, many pharmacologic challenges still exist.
The workshop provides a platform for state-of-the-art discussions of current topics fundamental to the optimal use of antiretroviral therapy including drug-drug interactions, pharmacokinetics of investigational agents and existing drugs, pharmacodynamics, drug dosing in special populations, post-marketing surveillance project, and regulatory considerations.
MEETING OBJECTIVES• To gather experts involved in clinical pharmacology from different disciplines in an interactive workshop setting
• To provide a platform for presentation and discussion of the latest developments in the field
• To map all current studies and results
• To translate new data to treatment guidelines
• To stimulate discussion and consensus on best practice
FORMATThis meeting consists of invited lectures, abstract-driven presentations, roundtable discussions, clinical case presentations and poster viewing sessions.
The meeting is abstract-driven. It is known as an excellent platform for young investigators to present their research. To ensure the quality of accepted abstracts, all submitted abstracts go through a blind, peer-reviewed process conducted by the members of the Program Committee, the Organizing Committee and the Scientific Committee.
UNIQUE MEETING FEATURESThe International Workshop on Clinical Pharmacology on HIV & Hepatitis:
• Is the premier Clinical Pharmacology meeting in the world
• Has a strong community of clinical pharmacologists and other healthcare professionals involved in this field
• Is an independent scientific platform for discussion and debate
TARGET AUDIENCEThe target audience of this workshop consist of experts in HIV and Hepatitis, clinical pharmacologists, pharmacists, educated clinicians, industry representatives, government representatives, PhD students and others involved in clinical pharmacology of HIV and Hepatitis therapy.
HIVHepatitis
5EVALUATION REPORT 17th International Workshop on Clinical Pharmacology of HIV & Hepatitis Therapy 8 - 10 June 2016, Washington, DC, USA
INTRODUCTION
HIVHepatitis
6EVALUATION REPORT 17th International Workshop on Clinical Pharmacology of HIV & Hepatitis Therapy 8 - 10 June 2016, Washington, DC, USA
MEETING PARTNERS
ACADEMIC PARTNERS
RELATED EVENTS
ASSOCIATED WEBSITES
ENDORSED BY
University of Torino
HIVHepatitis
7EVALUATION REPORT 17th International Workshop on Clinical Pharmacology of HIV & Hepatitis Therapy 8 - 10 June 2016, Washington, DC, USA
CORPORATE SUPPORTERS
PLATINUM LEVEL
SILVER LEVEL
SUPPORTER LEVEL
The organizers acknowledge the contributions of our corporate supporters that have made the 17TH INTERNATIONAL WORKSHOP ON CLINICAL PHARMACOLOGY OF HIV & HEPATITIS THERAPY possible:
HIVHepatitis
8EVALUATION REPORT 17th International Workshop on Clinical Pharmacology of HIV & Hepatitis Therapy 8 - 10 June 2016, Washington, DC, USA
PROGRAM COMMITTEE
CHARLES BOUCHER, MD, PhD Erasmus Medical Center The Netherlands
CHARLES FLEXNER, MD Johns Hopkins University USA
DAVID BACK, PhD University of Liverpool United Kingdom
DAVID BURGER, PharmD, PhD Radboud University Nijmegen The Netherlands
TERRENCE BLASCKE, MD Stanford University School of Medicine USA
COURTNEY FLETCHER, PharmD University of Nebraska Medical Center USA
GIOVANNI DI PERRI, MD, PhD University of Torino Italy
ANGELA KASHUBA, PharmD UNC Chapel Hill USA
HIVHepatitis
9EVALUATION REPORT 17th International Workshop on Clinical Pharmacology of HIV & Hepatitis Therapy 8 - 10 June 2016, Washington, DC, USA
ORGANIZING COMMITTEE
JÜRGEN ROCKSTROH, MD, PhD University of Bonn Germany
JENNIFER KISER, PharmD University of Colorado Health Sciences Center USA
SHIRLEY SEO, PhD Food and Drug Administration USA
JEAN-MICHEL PAWLOTSKY, MD, PhD Hôpital Henri Mondor, Université Paris XII France
JONATHAN SCHAPIRO, MD Sheba Medical Centre Israel
HIVHepatitis
10EVALUATION REPORT 17th International Workshop on Clinical Pharmacology of HIV & Hepatitis Therapy 8 - 10 June 2016, Washington, DC, USA
SCIENTIFIC COMMITTEE
Peter Anderson ..........................................................................University of Colorado, Denver, USA
Marta Boffito ..............................................................................St. Stephen’s Center, United Kingdom
Stefano Bonora ..........................................................................University of Torino, Italy
Tim Cressey ...............................................................................Chiang Mai University, Thailand
Rodolphe Garraffo ......................................................................Hopital Pasteur Nice, France
David Haas .................................................................................Vanderbilt University Medical Center, USA
Saye Khoo...................................................................................University of Liverpool, United Kingdom
Michael Kurowski.......................................................................Auguste-Victoria Hospital, Germany
Mohammed Lamorde ................................................................Infectious Diseases Institute, Uganda
Jacob Langness .........................................................................University of Colorado Hospital, USA
Lawrence Lee .............................................................................National University of Singapore, Singapore
Helen, McIlleron.........................................................................University of Cape Town, South Africa
José Moltó ..................................................................................Hospital Universitari Germans Trias i Pujol, Spain
Gilles Peytavin ............................................................................Bichat-Cl. Bernard Hospital, France
Elizabeth Phillips .......................................................................Royal Perth Hospital, Australia
Kellie Reynolds ..........................................................................Food and Drug Administration, USA
Kimberly Scarsi ..........................................................................University of Nebraska, USA
Kimberly Struble ........................................................................Food and Drug Administration, USA
Steve Taylor ................................................................................Heartland Hospital, United Kingdom
Alice Tseng .................................................................................Toronto General Hospital, Canada
Stefan Zeuzem ...........................................................................University of Frankfurt, Germany
HIVHepatitis
11EVALUATION REPORT 17th International Workshop on Clinical Pharmacology of HIV & Hepatitis Therapy 8 - 10 June 2016, Washington, DC, USA
INDUSTRY LIAISON BOARD
Tim Eley ......................................................................................BMS, USA
Daria Hazuda .............................................................................Merck, USA
Thomas Kakuda .........................................................................Alios BioPharma, USA
Charles La Porte ........................................................................Jansen Biologics, USA
Anita Mathias .............................................................................Gilead, USA
John McHutchison .....................................................................Gilead, USA
Rajeev Menon .............................................................................Abbvie, USA
Parul Patel .................................................................................ViiV Healthcare, USA
Stephen Piscitelli .......................................................................Roivant Sciences, USA
Manoli Vourvahis ........................................................................Pfizer, USA
HIVHepatitis
12EVALUATION REPORT 17th International Workshop on Clinical Pharmacology of HIV & Hepatitis Therapy 8 - 10 June 2016, Washington, DC, USA
PARTICIPANTS’ FEEDBACK
MEETING OBJECTIVESStrongly
agree
Agree Average Disagree (Strongly)
disagree
To gather experts involved in clinical pharmacology from different disciplines in an interactive workshop
setting
58% 40% 2% 0% 0%
To provide a platform for presentation and discussion of the latest developments in the field
58% 38% 4% 0% 0%
To map all current studies and results 44% 37% 17% 2% 0%
To translate new data to treatment guidelines 29% 31% 34% 6% 0%
To stimulate discussion and consensus on best practice
36% 53% 11% 0% 0%
GENERAL EVENT EXPERIENCEExcellent /
strongly agree
Good /agree Fair /neutral Fair /disagree Poor /
strongly
disagree
Overall event experience 54% 44% 2% 0% 0%
Opportunity of networking 53% 43% 4% 0% 0%
Content of the conference 43% 49% 8% 0% 0%
Time allocation for discussion 43% 49% 6% 2% 0%
Time allocation per presentation 55% 41% 4% 0% 0%
No commercial bias (product selling) perceived 55% 29% 12% 4% 0%
I would recommend this meeting to my peers 55% 41% 4% 0% 0%
I plan to attend this meeting next year 50% 39% 11% 0% 0%
HIVHepatitis
13EVALUATION REPORT 17th International Workshop on Clinical Pharmacology of HIV & Hepatitis Therapy 8 - 10 June 2016, Washington, DC, USA
PARTICIPANTS’ FEEDBACK
LECTURES
WEDNESDAY 8 JUNE
Opening session
Opening Lecture: Other Viruses: using Wolbachia to interrupt transmission of viral infections such as Dengue, Chikungunya and Zika Steven Kern, PhD - Bill & Melinda Gates Foundation, USA
Excellent Good Average Fair Poor
Interesting 56% 35% 7% 2% 0%
Relevance 19% 17% 30% 13% 21%
Performance 50% 46% 4% 0% 0%
THURSDAY 9 JUNE
Session 1: Pharmacokinetics in infants and young children
Abstract-driven presentations Excellent Good Average Fair Poor
Interesting 52% 42% 4% 0% 2%
Relevance 46% 35% 13% 6% 0%
Session 2: Hepatitis resistance and pharmacokinetics of DAAs
Role of Resistance Testing Shyam Kottilil, MBBS, PhD - Institute of Human Virology, University of Maryland, USA
Excellent Good Average Fair Poor
Interesting 51% 41% 8% 0% 0%
Relevance 31% 31% 24% 8% 6%
Performance 41% 51% 6% 2% 0%
The FDA Perspective on Hepatitis C Drug Resistance Patrick Harrington, PhD - U.S. Food and Drug Administration, USA
Excellent Good Average Fair Poor
Interesting 51% 45% 4% 0% 0%
Relevance 36% 34% 19% 6% 5%
Performance 47% 51% 2% 0% 0%
Abstract-driven presentations Excellent Good Average Fair Poor
Interesting 47% 47% 6% 0% 0%
Relevance 38% 38% 16% 4% 4%
Session 3: Compartmental penetration of Antiretrovirals
Abstract-driven presentations Excellent Good Average Fair Poor
Interesting 44% 49% 7% 0% 0%
Relevance 32% 56% 12% 0% 0%
HIVHepatitis
14EVALUATION REPORT 17th International Workshop on Clinical Pharmacology of HIV & Hepatitis Therapy 8 - 10 June 2016, Washington, DC, USA
PARTICIPANTS’ FEEDBACK
Session 4: Long Acting Antivirals
Target Concentrations Angela Kashuba, PharmD - University of North Carolina, Chapel Hill, USA
Excellent Good Average Fair Poor
Interesting 63% 31% 6% 0% 0%
Relevance 48% 37% 9% 6% 0%
Performance 67% 26% 7% 0% 0%
FDA Perspective on "oral run-in" phase Yodit Belew, MD - U.S. Food and Drug Administration, USA
Excellent Good Average Fair Poor
Interesting 33% 46% 17% 4% 0%
Relevance 33% 33% 17% 8% 9%
Performance 19% 66% 11% 2% 2%
ViiV - Cabotegravir Bill Spreen, PharmD - ViiV Healthcare, USA
Excellent Good Average Fair Poor
Interesting 48% 46% 6% 0% 0%
Relevance 39% 50% 6% 2% 4%
Performance 46% 50% 4% 0% 0%
Janssen - Rilpivirine Herta Crauwels, PhD - Janssen Infectious Diseases, Belgium
Excellent Good Average Fair Poor
Interesting 46% 41% 9% 4% 0%
Relevance 37% 42% 13% 4% 4%
Performance 26% 46% 24% 4% 0%
Abstract-driven Presentations: Excellent Good Average Fair Poor
Interesting 38% 50% 12% 0% 0%
Relevance 35% 46% 13% 0% 6%
Session 5: Back to the Future: 40 years of Clinical Pharmacology
Looking Backwards: Hormonal Contraception and ART Kimberly Scarsi, PharmD, MS, BCPS-ID – University of Nebraska, USA
Excellent Good Average Fair Poor
Interesting 51% 39% 8% 2% 0%
Relevance 35% 37% 22% 6% 0%
Performance 66% 30% 4% 0% 0%
Pharmacogenetics - Back to reality Andrew Owen, PhD, FRSB, FBPhS - University of Liverpool, United Kingdom
Excellent Good Average Fair Poor
Interesting 57% 33% 10% 0% 0%
Relevance 47% 31% 20% 2% 0%
Performance 58% 36% 4% 0% 2%
Will we see the Back of DDIs? Catia Marzolini, PharmD, PhD - University Hospital of Basel, Switzerland
Excellent Good Average Fair Poor
Interesting 59% 33% 8% 0% 0%
Relevance 55% 37% 8% 0% 0%
Performance 61% 33% 6% 0% 0%
The ‘Back Side’ of Compartments Saye Khoo, MD, PhD - University of Liverpool, United Kingdom
Excellent Good Average Fair Poor
Interesting 59% 37% 2% 2% 0%
Relevance 41% 36% 21% 2% 0%
Performance 63% 28% 7% 2% 0%
HIVHepatitis
15EVALUATION REPORT 17th International Workshop on Clinical Pharmacology of HIV & Hepatitis Therapy 8 - 10 June 2016, Washington, DC, USA
PARTICIPANTS’ FEEDBACK
Back-terial co-infections Mohammed Lamorde, MD, PhD - Infectious Diseases Institute, Uganda
Excellent Good Average Fair Poor
Interesting 53% 45% 0% 2% 0%
Relevance 45% 31% 19% 5% 0%
Performance 56% 37% 5% 2% 0%
Backing up clinical data with modelling Marco Siccardi, PhD - University of Liverpool, United Kingdom
Excellent Good Average Fair Poor
Interesting 62% 31% 5% 2% 0%
Relevance 50% 29% 14% 2% 5%
Performance 67% 26% 5% 2% 0%
FRIDAY 10 JUNESession 6: Clinical Guidance on how to interpret DDI’s
Specific Complex Interactions (mechanic presentation) David Burger, PharmD, PhD – Radboudumc, Nijmegen, The Netherlands
Excellent Good Average Fair Poor
Interesting 62% 33% 5% 0% 0%
Relevance 60% 27% 9% 4% 0%
Performance 58% 40% 0% 2% 0%
Clinical translation of "Amber" Jonathan Schapiro, MD – Sheba Medical Center, Israel
Excellent Good Average Fair Poor
Interesting 62% 38% 0% 0% 0%
Relevance 61% 31% 8% 0% 0%
Performance 54% 31% 15% 0% 0%
Real life cases Elise Smolders – Radboudumc, Nijmegen, The Netherlands
Excellent Good Average Fair Poor
Interesting 50% 33% 13% 2% 2%
Relevance 42% 29% 21% 6% 2%
Session 7: PK/PD of new and existing antivirals: Abstract driven presentations
Abstract-driven Presentations: Excellent Good Average Fair Poor
Interesting 46% 50% 4% 0% 0%
Relevance 40% 46% 14% 0% 0%
Session 8: Clinical Pharmacology Updates on New Compounds (by company rep.)
Abstract-driven Presentations: Excellent Good Average Fair Poor
Interesting 51% 45% 4% 0% 0%
Relevance 50% 45% 5% 0% 0%
Poster Sessions
Poster session were: Excellent Good Average Fair Poor
Valuable 50% 48% 2% 0% 0%
Well
programmed
50% 42% 8% 0% 0%
HIVHepatitis
16EVALUATION REPORT 17th International Workshop on Clinical Pharmacology of HIV & Hepatitis Therapy 8 - 10 June 2016, Washington, DC, USA
PARTICIPANTS’ FEEDBACK
ORGANIZATIONExcellent Good Average Fair Poor
Content of electronic announcements 34% 49% 17% 0% 0%
Frequency of electronic announcements 29% 50% 15% 6% 0%
Information on coference website 37% 43% 14% 6% 0%
Online registration process 41% 46% 5% 8% 0%
Online abstract submission process 32% 56% 9% 0% 3%
Meeting venue 35% 44% 11% 6% 4%
Meeting room 40% 33% 21% 4% 2%
Audiovisuals 47% 35% 14% 4% 0%
Food & Beverage 50% 35% 11% 4% 0%
Onsite logistics 47% 43% 10% 0% 0%
Service level of Conference Secretariat 50% 38% 10% 2% 0%
PUBLICITYAttention was drawn to this meeting by:
0
5
10
15
20
25
30
35
I knew about this meeting by way of:
Attention was drawn to this meeting by:
0
10
20
30
40
50
60
Scientificprogram
Opportunity tomeet withcolleagues
Experiencefrom previous
meetings
Meetingobjectives
Meetinglocation
Other
I was motivated to attend this meeting by:
HIVHepatitis
17EVALUATION REPORT 17th International Workshop on Clinical Pharmacology of HIV & Hepatitis Therapy 8 - 10 June 2016, Washington, DC, USA
MEETING DEMOGRAPHICS
NUMBER OF PARTICIPANTSIn 2016 this meeting had 155 participants from 19 countries. Largest groups were from the United States (86), France (25), United Kingdom (11) and Canada (8).
The geographical distribution of participants is as follows:
USA 86
France 25
United Kingdom 11
Canada 8
The Netherlands 5
Italy 4
Chile 3
Thailand 2
Aruba 1
Australia 1
Belgium 1
China 1
Israel 1
Singapore 1
South Africa 1
Spain 1
Sweden 1
Switzerland 1
Uganda 1
PROFESSIONAL BACKGROUNDMain activity Mainly employed by:
Pharmacologist; 43%
Pharmacist; 20%
Researcher; 19%Other; 8%
Cl inician; 6%
Student; 5%
Marketing person; 1%
University; 34%
Hospital; 30%Industry; 23%
Government; 9%
NGO; 2%
Other; 2%
Area of expertise:
HIV; 53%
Hepatitis; 35%
Other; 12%
HIVHepatitis
18EVALUATION REPORT 17th International Workshop on Clinical Pharmacology of HIV & Hepatitis Therapy 8 - 10 June 2016, Washington, DC, USA
CONCLUSION
The overall opinion of the meeting was very positive, as can be deducted from the above scores. Participants were satisfied with the scientific content of the workshop as well as with the logistics and the format of the program. The Organizing Committee and the Organizing Secretariat are very pleased with the evaluation results of this workshop. The success and importance of this workshop have underlined the need for continuation. The 18th edition of the International Workshop on Clinical Pharmacology of Antiviral Therapy is scheduled to take place 14 - 16 June in Chicago, IL, USA.
HIVHepatitis
19EVALUATION REPORT 17th International Workshop on Clinical Pharmacology of HIV & Hepatitis Therapy 8 - 10 June 2016, Washington, DC, USA
LIST OF PARTICIPANTS
Last name, name Institute Country
Aboud,Michael ViiV Healthcare United Kingdom
Adkison,Kimberly ViiV Healthcare USA
Anderson,Peter L. University of Colorado Denver USA
Arya,Vikram FDA USA
Au,Stanley FDA USA
Azara,Maria Merck Sharp & Dome (IA) LLC Agencia Chile Chile
Back,David University of Liverpool United Kingdom
Bednasz,Cindy University at Buffalo USA
Berger-De Jong,Inge HOH Aruba
Bernal,Fernando Hospital San Juan de Dios Chile
Bethell,Richard Medivir AB Sweden
Blaschke,Terrence Stanford University School of Medicine USA
Bollen,Pauline D.J. Radboud Universitair Medisch Centrum The Netherlands
Bonora,Stefano University of Torino Italy
Boucher,Charles Erasmus Medical Center The Netherlands
Boussairi,Abdelghani Ch de Saint-Denis France
Brooks,Kristina NIH Clinical Center USA
Burger,David Radboud Universitair Medisch Centrum The Netherlands
Calcagno,Andrea University of Torino Italy
Carole,Jeangirard Janssen France
Chavada,Ruchir Pathology North Australia
Chen,Jingxian University of North Carolina at Chapel Hill USA
Chen,Xinhui University of Colorado USA
Choi,Su-Young the Food and Drug Administration USA
Clarke,Diana Boston Medical Center USA
Colbers,Angela Radboud Universitair Medisch Centrum The Netherlands
Collins,Simon HIV i-Base United Kingdom
Cortes,Claudia University of Chile Chile
Cosler,Patricia Janssen Services, LLC USA
Cotterlaz,Caroline Janssen France
Cottrell,Mackenzie University of North Carolina USA
Crauwels,Herta Janssen Infectious Diseases Belgium
Cressey,Tim Chiang Mai University Thailand
Curley,Paul University of Liverpool United Kingdom
Custodio,Joseph Gilead Sciences USA
D'Amico,Ronald ViiV Healthcare USA
D'Avolio,Antonio University of Turin Italy
De Wet,Joseph Spectrum-health clinic Canada
Di Perri,Giovanni University of Torino Italy
Dickinson,Laura University of Liverpool United Kingdom
Djossou,Felix Centre hospitalier Andrée-Rosemon France
Donovan,Brian ViiV Healthcare USA
HIVHepatitis
20EVALUATION REPORT 17th International Workshop on Clinical Pharmacology of HIV & Hepatitis Therapy 8 - 10 June 2016, Washington, DC, USA
Last name, name Institute Country
Dumond,Julie UNC Eshelman School of Pharmacy USA
Dunnington,Katherine Celerion USA
Eley,Timothy Bristol-Myers Squibb USA
Feng,Hwa-ping Merck USA
Fletcher,Courtney University of Nebraska USA
Flexner,Charles Johns Hopkins University USA
Ford,Susan Parexel International USA
Fuchs,John ViiV Healthcare USA
Gagnieu,Marie-Claude Hôpital Eduard Herriot France
Gair,Robert Positive Health Services Canada
Garimella,Tushar Bristol-Myers Squibb USA
Garraffo,Rodolphe Hôpital Pasteur France
George,Jomy Clinical Center USA
German,Polina Gilead Sciences USA
Gregoire,Matthieu CHU Nantes France
Gunasekaran,Suvai Northwestern University Feinberg School of Medicine USA
Haas,David Vanderbilt University Medical Center USA
Harrington,Patrick FDA USA
Jimmerson,Leah University of Colorado USA
Jordan,Julie Teva Pharmaceuticals USA
Kakuda,Thomas Alios BioPharma, Inc. USA
Kashuba,Angela UNC Eshelman School of Pharmacy USA
Kern,Steven Bill & Melinda Gates Foundation USA
Khoo,Saye University of Liverpool United Kingdom
Kim,Nancy Merck & Co. USA
King,Jennifer Abbvie USA
Kirby,Brian Gilead Sciences USA
Kiser,Jennifer University of Colorado Denver USA
Klem,Katherine Bristol-Myers Squibb USA
Kong,Harold ViiV Healthcare USA
Koteff,Justin ViiV Healthcare USA
Kottilil,Shyam Institute of Human Virology, USA
Kreutzwiser,Denise University Health Network Canada
Kumar,Parag NIH USA
Lafont,Bertrand Gilead France
Lamorde,Mohammed Infectious Diseases Institute Uganda
Lamoureux,Fabien CHU Rouen France
Landgraf,Nathalie Centre Hospitalier France
Le,Minh Patrick Hôpital Bichat-Claude Bernard France
Lee,Lawrence National University of Singapore Singapore
Leger,Paul Vanderbilt University School of Medicine USA
Lehrman,Sandra Merck USA
LIST OF PARTICIPANTS
HIVHepatitis
21EVALUATION REPORT 17th International Workshop on Clinical Pharmacology of HIV & Hepatitis Therapy 8 - 10 June 2016, Washington, DC, USA
Last name, name Institute Country
Lemaitre,Florian Hopital Pontchaillou - Chu De Rennes France
Liu,Siyu University of Southern California USA
MacBrayne,Christine University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences
USA
Martel,Dominic Centre Hospitalier de l'Université de Montréal Canada
Marzolini,Catia University Hospital Basel Switzerland
Mascolini,Mark Medical Writer USA
Mathias,Anita Gilead Sciences USA
Maubert,Marie Anne Assistance Publique Hôpitaux de Paris France
McAllister,Kevin University of Colorado School of Medicine USA
McIlleron,Helen University of Cape Town South Africa
Merrill,Deanna ViiV Healthcare USA
Metsu,David CHU Toulouse - Purpan France
Mirochnick,Mark Boston University USA
Mogalian,Erik Gilead Sciences USA
Mogalian,Erik Gilead Sciences USA
Moguilnikov,Maria ViiV Healthcare France
Moltó,José Hospital Universitari Germans Trias i Pujol Spain
Monchaud,Caroline Hôpital Dupuytren France
Moore,Katy ViiV Healthcare USA
Mukherjee,Dwaipayan AbbVie USA
Muret,Patrice Hôpital Jean Minjoz France
Naik,Sarjita Gilead Sciences USA
Neant,Nadege Aix-Marseille University France
Owen,Andrew University of Liverpool United Kingdom
Patarroyo,Jimena ViiV Healthcare USA
Patel,Parul ViiV Healthcare USA
Peytavin,Gilles Hopital Bichat Claude Bernard France
Phillips,Elizabeth Vanderbilt University School of Medicine USA
Podany,Anthony University of Nebraska USA
Poirier,Jean-Marie Saint-Antoine University Hospital France
Pope,Camille AbbVie USA
Quaranta,Sylvie Hôpital de la Timone France
Rakhmanina,Natella Children's National Medical Center USA
Ritchings,Corey Bristol-Myers Squibb USA
Rizk,Matthew Merck Sharpe & Dohme Corp., a subsidiary of Merck and Co., Inc. USA
Roberts,Owain University of Liverpool United Kingdom
Robillard,Kevin ViiV Healthcare ULC Canada
Rogatto,Felipe Gilead Sciences Europe Ldt United Kingdom
Rublein,John Gilead Sciences USA
Sampson,Mario Food and Drug Administration USA
Scarsi,Kimberly University of Nebraska USA
LIST OF PARTICIPANTS
HIVHepatitis
22EVALUATION REPORT 17th International Workshop on Clinical Pharmacology of HIV & Hepatitis Therapy 8 - 10 June 2016, Washington, DC, USA
Last name, name Institute Country
Schapiro,Jonathan Sheba Medical Center Israel
Seggev,Michael SeggevM Consulting LLC USA
Seifert,Sharon University of Colorado Denver USA
Seo,Shirley FDA USA
Sevinsky,Heather Bristol-Myers Squibb USA
Shang,Hong The First Affliated Hospital of China Medical University China
Sheehan,Nancy McGill University Health Centre Canada
Siccardi,Marco University of Liverpool United Kingdom
Smolders,Elise Radboud Universitair Medisch Centrum The Netherlands
Solas Chesneau,Caroline Hôpital de la Timone France
Spreen,William ViiV Healthcare USA
Sutton,Kenneth ViiV Healthcare USA
Taburet,Anne-Marie Hôpital Bicêtre France
Teppler,Hedy Merck USA
Terrail,Nicolas Hôpital Lapeyronie France
Thammajaruk,Narukjaporn HIV Netherlands Australia Thailand Research Collaboration (HIV-NAT), Thai Red Cr
Thailand
Therrien,Rachel Centre Hospitalier de l'Université de Montréal Canada
Thompson,Corbin UNC Chapel Hill USA
Trezza,Christine ViiV Healthcare USA
Tseng,Alice Toronto General Hospital Canada
Venisse,Nicolas Centre Hospitalier Universitaire France
Vourvahis,Manoli Pfizer, Inc USA
Weber,Michael University of North Carolina at Chapel Hill USA
Wolford,Dennis Merck Sharpe & Dohme Corp., a subsidiary of Merck and Co., Inc. USA
Yau,Stuart Gilead Sciences Ltd United Kingdom
Yoder,Christian Food and Drug Administration USA
Younis,Islam FDA USA
Zhang,Qingling Alios BioPharma USA
Zhengyu,Xue Parexel International USA
Zhuang,Luning FDA USA
LIST OF PARTICIPANTS
Top Related